PCM
ADVM

Prelude Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Prelude Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-40
Closed -$6K – 1449
2015
Q2 		$6K Buy
+40
New +$13.5K ﹤0.01% 1604

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prelude Capital Management's ADVM Position: Q4 2020 in Review

Prelude Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2020, closing a stake of 740 shares — an estimated $76K sold.

Prelude Capital Management first reported a position in ADVM in Q1 2017 and held it in 4 quarters. The position peaked at $76K in Q3 2020. 155 funds tracked by Wall St. Rank hold ADVM as of Q4 2020.

  • Prelude Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 740 Adverum Biotechnologies shares in Q4 2020, an estimated $76K.
  • Prelude Capital Management first reported a position in Adverum Biotechnologies in Q1 2017 and held it in 4 quarters.
  • Prelude Capital Management's Adverum Biotechnologies position peaked at $76K in Q3 2020.
  • 155 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.